IM-412 inhibits the invasion of human breast carcinoma cells by blocking FGFR-mediated signaling

Oncology Reports

Volumn 34, Issue 5, 2015, Pages 2731-2737

  Jung, Seung Youn ^a   Yi, Jae Youn ^b   Kim, Mi Hyoung ^a   Song, Kyung Hee ^a   Kang, Seong Mook ^a   Ahn, Jiyeon ^a   Hwang, Sang Gu ^a   Nam, Ky Youb ^b   Song, Jie Young ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b Asan Medical Center   (South Korea)

Author keywords

Epithelial tomesenchymal transition; FGFR; IM 412; Invasion; Migration; Triple negative breast cancer

Indexed keywords

3 (2 CHLOROBENZYL) 1,7 DIMETHYL 1H IMIDAZO[2,1 F]PURINE 2,4 (3H,8H)DIONE; ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; SMAD2 PROTEIN; SMAD3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; 3-(2-CHLOROBENZYL)-1,7-DIMETHYL-1H-IMIDAZO(2,1-F)PURINE-2,4(3H,8H)-DIONE; FGFR1 PROTEIN, HUMAN; FGFR3 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; PURINE DERIVATIVE; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA CELL; CANCER INHIBITION; CARCINOMA CELL; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; CELL DIFFERENTIATION; CELL MOTION; DRUG EFFECTS; FEMALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BIOMARKERS, TUMOR; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; IMIDAZOLES; PHOSPHORYLATION; PURINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84941955563     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4249     Document Type: Article

References (32)

1. Derynck R, Muthusamy BP and Saeteurn KY: Signaling pathway cooperation in TGF-β-induced epithelial-mesenchymal transition. Curr Opin Cell Biol 31: 56-66, 2014.
2. Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428, 2009.
3. Xu J, Lamouille S and Derynck R: TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19: 156-172, 2009.
4. Fan YL, Zheng M, Tang YL and Liang XH: A new perspective of vasculogenic mimicry: EMT and cancer stem cells (Review). Oncol Lett 6: 1174-1180, 2013.
5. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY and Bapat SA: Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 27: 2059-2068, 2009.
6. Lee JK, Joo KM, Lee J, Yoon Y and Nam DH: Targeting the epithelial to mesenchymal transition in glioblastoma: The emerging role of MET signaling. Onco Targets Ther 7: 1933-1944, 2014.
7. Kotiyal S and Bhattacharya S: Breast cancer stem cells, EMT and therapeutic targets. Biochem Biophys Res Commun 453: 112-116, 2014.
8. Tania M, Khan MA and Fu J: Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol 35: 7335-7342, 2014.
9. Massagué J: TGFβ signalling in context. Nat Rev Mol Cell Biol 13: 616-630, 2012.
10. Katoh M and Nakagama H: FGF receptors: Cancer biology and therapeutics. Med Res Rev 34: 280-300, 2014.
11. Turner N and Grose R: Fibroblast growth factor signalling: From development to cancer. Nat Rev Cancer 10: 116-129, 2010.
12. Brooks AN, Kilgour E and Smith PD: Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 18: 1855-1862, 2012.
13. Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, Ayala GE, Peterson LE, Ittmann M and Spencer DM: Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 12: 559-571, 2007.
14. Feng S, Zhou L, Nice EC and Huang C: Fibroblast growth factor receptors: Multifactorial-contributors to tumor initiation and progression. Histol Histopathol 30: 13-31, 2015.
15. Haugsten EM, Wiedlocha A, Olsnes S and Wesche J: Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res 8: 1439-1452, 2010.
16. Park S, Ahn JY, Lim MJ, Kim MH, Lee SL, Yun YS, Jeong G and Song JY: IM-412 inhibits transforming growth factor betainduced fibroblast differentiation in human lung fibroblast cells. Biochem Biophys Res Commun 399: 268-273, 2010.
17. Yi JY, Hur KC, Lee E, Jin YJ, Arteaga CL and Son YS: TGFbeta1-mediated epithelial to mesenchymal transition is accompanied by invasion in the SiHa cell line. Eur J Cell Biol 81: 457-468, 2002.
18. Hagler AT, Lifson S and Dauber P: Consistent force field studies of intermolecular forces in hydrogen-bonded crystals. 2. A benchmark for the objective comparison of alternative force fields. J Am Chem Soc 101: 5122-5130, 1979.
19. Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15: 178-196, 2014.
20. Cailleau R, Young R, Olivé M and Reeves WJ Jr: Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 53: 661-674, 1974.
21. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, Kwei KA, Hernandez-Boussard T, Wang P, Gazdar AF, et al: Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 4: e6146, 2009.
22. Schmadeka R, Harmon BE and Singh M: Triple-negative breast carcinoma: Current and emerging concepts. Am J Clin Pathol 141: 462-477, 2014.
23. Yadav BS, Sharma SC, Chanana P and Jhamb S: Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 5: 125-133, 2014.
24. Ciardiello F and Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 358: 1160-1174, 2008.
25. E llis LM and Hicklin DJ: VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer 8: 579-591, 2008.
26. Grose R and Dickson C: Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 16: 179-186, 2005.
27. Takeuchi K and Ito F: Receptor tyrosine kinases and targeted cancer therapeutics. Biol Pharm Bull 34: 1774-1780, 2011.
28. Hough C, Radu M and Doré JJ: Tgf-beta induced Erk phosphorylation of smad linker region regulates smad signaling. PLoS One 7: e42513, 2012.
29. Kamato D, Burch ML, Piva TJ, Rezaei HB, Rostam MA, Xu S, Zheng W, Little PJ and Osman N: Transforming growth factor-β signalling: Role and consequences of Smad linker region phosphorylation. Cell Signal 25: 2017-2024, 2013.
30. Wendt MK, Taylor MA, Schiemann BJ, Sossey-Alaoui K and Schiemann WP: Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers. Breast Cancer Res 16: R24, 2014.
31. Tiong KH, Mah LY and Leong C-O: Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers. Apoptosis 18: 1447-1468, 2013.
32. Nguyen PT, Tsunematsu T, Yanagisawa S, Kudo Y, Miyauchi M, Kamata N and Takata T: The FGFR1 inhibitor PD173074 induces mesenchymal-epithelial transition through the transcription factor AP-1. Br J Cancer 109: 2248-2258, 2013.